VIEW PUBLICATIONS Dosimetry Characterization of a Multibeam Radiotherapy Treatment for Age-Related Macular Degeneration Kilovoltage Stereotactic Radiosurgery for Age-related Macular Degeneration: Assessment of Optic Nerve Dose and Patient Effective Dose IN THE PRESS 1/5/2010 - Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD 10/20/2009 - Oraya Therapeutics to present at Ophthalmology Innovations Summit

Developing noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye. Oraya Therapeutics is currently testing its first application of the IRay™ system. ABOUT ORAYA   OUR TEAM   CLINICAL TRIALS Dedicated to developing noninvasive therapies for diseases of the eye. Leadership in producing innovative medical technologies. The first clinical indication under study for the IRay system is treatment of wet AMD.

Copyright © 2009 Oraya Therapeutics, Inc. All rights reserved. | (510) 456-3700 | info@orayainc.com
Note: IRay™ is an investigational device. Limited by Federal (U.S.A.) law to investigational use.